Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. TC Biopharm (Holdings) Plc
  6. Summary
    TCBP   US87807D1037

TC BIOPHARM (HOLDINGS) PLC

(TCBP)
  Report
End-of-day quote Nasdaq  -  2022-08-04
0.3780 USD   +0.69%
07/29European ADRs Move Higher in Friday Trading
MT
07/13Advancing cell therapies - γδ T cells and the combination factor
AQ
06/07TC Biopharm Completes $4 Million Stock Sale
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
0.3498 0.345 0.365 0.3754 0.378 Last
548459 349288 2497099 454637 282938 Volume
-3.00% -1.37% +5.80% +2.85% +0.69% Change
Estimated financial data (e) (USD)
Sales 2022 1,60 M - -
Net income 2022 -15,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,76x
Yield 2022 -
Sales 2023
Net income 2023
Net Debt 2023
P/E ratio 2023
Yield 2023
Capitalization 14,4 M 14,4 M -
Capi. / Sales 2022 8,99x
EV / Sales 2023
Nbr of Employees 76
Free-Float 40,9%
More Financials
Company
TC BioPharm Limited is a clinical-stage cell therapy company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf... 
Read more
More about the company
All news about TC BIOPHARM (HOLDINGS) PLC
07/29European ADRs Move Higher in Friday Trading
MT
07/13Advancing cell therapies - γδ T cells and the combination factor
AQ
06/07TC Biopharm Completes $4 Million Stock Sale
MT
06/03Top Premarket Decliners
MT
06/03TC BioPharm Prices Offering at $0.40/ADS
MT
05/26Top Premarket Gainers
MT
05/18TC Biopharm Announces Formation of Scientific Advisory Board
CI
05/17European ADRs Move Higher in Tuesday Trading
MT
05/16European ADRs Move Higher in Monday Trading
MT
05/13TC Biopharm Plc Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/13European ADRs Move Higher in Friday Trading
MT
05/13TC Biopharm Plc Auditor Raises 'Going Concern' Doubt
CI
05/12European ADRs Decline in Thursday Trading
MT
05/05European ADRs Decline in Thursday Trading
MT
04/06TC Biopharm Secures UK Trademark for CryoTC Cell Freezing Process
MT
More news
News in other languages on TC BIOPHARM (HOLDINGS) PLC
07/29Les ADR européens sont en hausse vendredi
06/07TC Biopharm conclut une vente d'actions de 4 millions de dollars
06/03TC BioPharm fixe le prix de son offre à 0,40 $/ADS
05/18TC Biopharm annonce la formation d'un conseil consultatif scientifique
05/17Les ADR européens sont en hausse mardi
More news
Analyst Recommendations on TC BIOPHARM (HOLDINGS) PLC
More recommendations
Chart TC BIOPHARM (HOLDINGS) PLC
Duration : Period :
TC Biopharm (Holdings) Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,38 $
Average target price 5,00 $
Spread / Average Target 1 223%
EPS Revisions
Managers and Directors
Bryan Kobel Chief Executive Officer & Director
Martin Edward Thorp Chief Financial Officer & Director
Michael Leek Executive Chairman
Angela Scott Chief Operating Officer
Mark L. Bonyhadi Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TC BIOPHARM (HOLDINGS) PLC0.00%14
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235